# Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.

> **NCT03735966** · PHASE2 · COMPLETED · sponsor: **Henan Cancer Hospital** · enrollment: 75 (actual)

## Conditions studied

- HER2 Positive Breast Cancer

## Interventions

- **DRUG:** Pyrotinib plus trastuzumab and docetaxel and carboplatin

## Key facts

- **NCT ID:** NCT03735966
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-20
- **Primary completion:** 2020-10-20
- **Final completion:** 2020-10-20
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2022-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03735966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03735966, "Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03735966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*